Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 22Plasma cell 2Other solid neoplasm 2Lymphoid 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × 1-dodecylpyridoxal × Other hematologic neoplasm × Clear all
NCT03419494 2018-02-05

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡